Inmazeb

E468966

Inmazeb is an FDA-approved monoclonal antibody cocktail used to treat infections caused by Zaire ebolavirus.

All labels observed (1)

Label Occurrences
Inmazeb canonical 2

How this entity was disambiguated

Statements (49)

Predicate Object
instanceOf FDA-approved drug ⓘ
antiviral drug ⓘ
biologic medicinal product ⓘ
monoclonal antibody cocktail ⓘ
prescription drug ⓘ
adverseEffect chills ⓘ
diarrhea ⓘ
hypotension ⓘ
hypoxia ⓘ
nausea ⓘ
pyrexia ⓘ
shivering ⓘ
tachycardia ⓘ
vomiting ⓘ
approvalDate 2020 ⓘ
approvalStatus approved ⓘ
approvalType FDA-approved ⓘ
blackBoxWarning hypersensitivity reactions ⓘ
infusion-related reactions ⓘ
countryOfApproval United States of America ⓘ
dosageForm solution for intravenous infusion ⓘ
hasATCCode J06BD ⓘ
hasComponent atoltivimab ⓘ
linked to: maftivimab

maftivimab ⓘ
odesivimab ⓘ
hasINN atoltivimab ⓘ
maftivimab ⓘ
odesivimab ⓘ
indication treatment of infection caused by Zaire ebolavirus ⓘ
isCombinationProduct true ⓘ
isFirstInClass first FDA-approved treatment for Zaire ebolavirus infection ⓘ
isHumanMonoclonalAntibody true ⓘ
lactationUse caution advised ⓘ
legalStatus prescription only ⓘ
mechanismOfAction binds to Zaire ebolavirus glycoprotein ⓘ
neutralizes Zaire ebolavirus ⓘ
pharmacologicalClass antiviral monoclonal antibody ⓘ
monoclonal antibody ⓘ
pregnancyCategory insufficient human data ⓘ
regulatoryAgencyApproval U.S. Food and Drug Administration ⓘ
riskPopulation hospitalized patients with Zaire ebolavirus infection ⓘ
routeOfAdministration intravenous infusion ⓘ
storageCondition refrigerated ⓘ
targetOrganism Zaire ebolavirus ⓘ
therapeuticArea infectious disease ⓘ
virology ⓘ
treats Ebola virus disease caused by Zaire ebolavirus ⓘ
Zaire ebolavirus infection ⓘ
usedIn treatment of Ebola virus disease outbreaks ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

REGN-EB3 → brandName → Inmazeb ⓘ
maftivimab → partOf → Inmazeb ⓘ